ESYMLIN owner Contact Information online
from Amylin Pharmaceuticals, Inc.
ESYMLIN
US serial number:85019216
Application filling date:Apr. 21, 2010
Register:Principal
Mark type:Trademark
Status:Abandoned because no Statement of Use or Extension Request timely filed after Notice of Allowance was issued. To view all documents in this file, click on the Trademark Document Retrieval link at the top of this page.
Status date:Apr. 09, 2012
Publication date:Jul. 13, 2010
Abandoned date:Apr. 09, 2012
Standard character claim:Yes. The mark consists of standard characters without claim to any particular font style, size, or color.
Mark drawing type:4 - STANDARD CHARACTER MARK
Goods and services:For: Pharmaceutical preparations, namely, pharmaceutical preparations for use in the treatment and prevention of metabolic disorders, endocrine conditions and disorders, diabetes, diabetic complications, and hormonal diseases and disorders
International C
Services:Pharmaceutical preparations
namely
pharmaceutical preparations for use in the treatment and prevention of metabolic disorders
endocrine conditions and disorders
diabetes
diabetic complications
and hormonal diseases and disorders
Current owner owner name:Amylin Pharmaceuticals, Inc.
Current owner owner address:9360 Towne Centre Drive
San Diego,
CALIFORNIA
UNITED STATES
92121
Current owner legal entity type:CORPORATION
Current owner state or country:DELAWARE
Attorney name:Edward D. Grieff
Attorney email:trademarks@amylin.com
Attorney docket number:SMLNW02-US03
Attorney email authorized:Yes
Correspondent name address:EDWARD D. GRIEFF
AMYLIN PHARMACEUTICALS, INC.
9360 TOWNE CENTRE DR
SAN DIEGO,
CALIFORNIA
UNITED STATES
92121-3057
Correspondent phone:858-552-2200
Correspondent email:trademarks@amylin.com
Correspondent fax:858-552-1936
Correspondent email authorized:Yes
Trademark staff tm attorney:LEVINE, HOWARD B
Trademark staff law office assigned ESYMLIN:LAW OFFICE 115
Latest trademarks
Popular owners
Glaxo Group Limited (173) Novartis AG (130) JOHNSON & JOHNSON (124) Millennium Pharmaceuticals, Inc. (54) Eli Lilly and Company (51) Windmill Health Products, LLC (46) Bayer Aktiengesellschaft (44) SANOFI (41) Wyeth LLC (41) Pfizer Inc. (39) Forest Laboratories, Inc. (34) Bristol-Myers Squibb Company (33) Vital Health Pharmaceuticals, Inc. (31) Primary Investments Group Limited (28) S. C. Johnson & Son, Inc. (28) MERCK SHARP & DOHME CORP. (27) Futurebiotics, LLC (26) MONSTER ENERGY COMPANY (19) Scott Riddell (17) Biocept, Inc. (16)Popular publication dates
Mar. 08, 2011 Mar. 15, 2011 Mar. 22, 2011 Nov. 16, 2010 Mar. 29, 2011 Apr. 12, 2011 Apr. 19, 2011 Oct. 19, 2010 Oct. 26, 2010 Apr. 26, 2011 Feb. 15, 2011 Oct. 05, 2010 Oct. 12, 2010 Jan. 25, 2011 Sep. 21, 2010 Jan. 11, 2011 Feb. 22, 2011 Nov. 23, 2010 Sep. 28, 2010 Apr. 05, 2011Similar brands
